Detalhe da pesquisa
1.
AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2.
J Chem Inf Model
; 63(5): 1438-1453, 2023 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36808989
2.
Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study.
J Chem Inf Model
; 61(11): 5469-5483, 2021 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34666487
3.
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2.
Nat Commun
; 14(1): 1733, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36977673
4.
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity.
Res Sq
; 2022 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35169792
5.
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
Nat Commun
; 13(1): 2268, 2022 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477935
6.
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2.
Res Sq
; 2022 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35898342
7.
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2.
Res Sq
; 2022 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34642689
8.
Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19.
ACS Pharmacol Transl Sci
; 3(6): 1278-1292, 2020 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33330842